Biochemistry of the endogenous ligands of cannabinoid receptors

Neurobiology of Disease

Volumn 5, Issue 6, 1998, Pages 386-404

  Di Marzo, Vincenzo ^a   Deutsch, Dale G ^b  

^a CNR   (Italy)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ACYLGLYCEROL LIPASE; ADENYLATE CYCLASE; AMIDASE; ANANDAMIDE; CALCIUM CHANNEL; CANNABINOID; CANNABINOID RECEPTOR; ENZYME INHIBITOR; FATTY ACID DERIVATIVE; LIGAND; PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

ARTICLE; BIOCHEMISTRY; BIOSYNTHESIS; HUMAN; NERVOUS SYSTEM; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

EID: 0032459475     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.1998.0214     Document Type: Article

References (123)

1. Devane W. A., Dysarz F. A., Johnson M. R., Melvin L. S., Howlett A. C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
2. Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C., Bonner T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
3. Munro S., Thomas K. L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
4. Devane W. A., Hanus L., Breuer A., Pertwee R. G., Stevenson L. A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain costituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
5. Nye J. S., Voglmayer S., Martenson R. E., Snyder S. H. Myelin basic protein is an endogenous inhibitor of the high affinity cannabinoid binding site in brain. J. Neurochem. 50:1988;1170-1178.
6. 2+. J. Neurochem. 58:1992;780-782.
7. Evans D. M., Lake J. T., Johnson M. R., Howlett A. C. Endogenous cannabinoid receptor binding activity released from rat brain slices by depolarization. J. Pharmacol. Exper. Ther. 268:1994;1271-1277.
8. Fride E., Mechoulam R. Pharmacological activity of the cannabinoid agonist anandamide, a brain constituent. Eur. J. Pharmacol. 231:1993;313-314.
9. Crawley J. N., Corwin R. L., Robinson J. K., Felder C. C., Devane W. A., Axelrod J. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol. Biochem. Behav. 46:1993;967-972.
10. Vogel L., Barg J., Levy R., Saya D., Heldman E., Mechoulam R. Anandamide, an brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase. J. Neurochem. 61:1993;352-355.
11. Felder C. C., Briley E. M., Axelrod J., Simpson J. T., Mackie K., Devane W. A. Anandamide, an endogenous cannabinomimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA. 90:1993;7656-7660.
12. Devane W. A. New dawn of cannabinoid pharmacology. Trends Pharmacol. Sci. 15:1994;40-41.
13. Mechoulam R., Hanus L., Martin B. R. Search for endogenous ligands of the cannabinoid receptor. Biochem. Pharmacol. 48:1994;1537-1544.
14. Di Marzo V., Fontana A. Anandamide, an endogenous cannabinomimetic eicosanoid: 'Killing two birds with one stone'. Prostagl. Leuk. Ess. Fatty Acids. 53:1995;1-11.
15. Di Marzo V., De Petrocellis L., Bisogno T., Maurelli S. Pharmacology and physiology of the endogenous cannabimimetic mediator anandamide. J. Drug Dev. Clin. Pract. 7:1995;199-219.
16. Berdyshev E. V., Boichot E., Lagente V. Anandamide - A new look on fatty acid ethanolamides. J. Lipid Med. Cell Signal. 15:1996;49-67.
17. Di Marzo V., De Petrocellis L. The endogenous cannabinoid signalling system: Chemistry, biochemistry and physiology. Internet J. Sci. Biol. Chem. 1:1997.
18. Felder C. C., Nielsen A., Briley E. M., Palkovitis M., Priller J., Axelrod J., Nguyen D. N., Richardson J. M., Riggin R. M., Koppel G. A., Paul S. M., Becker G. W. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett. 393:1996;231-235.
19. Sugiura T., Kondo S., Sukagawa A., Tonegawa T., Nakane S., Yamashita A., Ishima Y., Waku K. Transacylase-mediated and phosphodiesterase-mediated synthesis ofN. Eur. J. Biochem. 240:1996;53-62.
20. 2+. Biochem. Biophys. Res. Commun. 218:1996;113-117.
21. Schmid P. C., Krebsbach R. J., Perry S. R., Dettmer T. M., Maassen J. L., Schmid H. H. O. Occurrence and postmortem generation of ananadamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett. 375:1995;117-120.
22. 9. Biochem. Pharmacol. 49:1995;855-858.
23. Di Marzo V., De Petrocellis L., Sepe N., Buono A. Biosynthesis of anandamide and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma cells. Biochem. J. 316:1996;977-984.
24. Bisogno T., Maurelli S., Melck D., De Petrocellis L., Di Marzo V. Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. J. Biol. Chem. 272:1997;3315-3323.
25. Deutsch D. G., Goligorsky M. S., Schmid P. C., Krebsbach R. J., Schmid H. H. O., Das S. K., Dey S. K., Arreaza G., Thorup C., Stefano G. B., Moore L. C. Production, binding and vascular actions of anandamide in the rat kidney. J. Clin. Invest. 100:1997;1538-1546.
26. Bisogno T., Ventriglia M., Mosca M., Milone A., Cimino G., Di Marzo V. Occurrence and metabolism of anandamide and related acylethanolamides in ovaries of the sea urchinParacentrotus lividus. Biochim. Biophys. Acta. 1345:1997;338-348.
27. Sepe N., De Petrocellis L., Montanaro F., Cimino G., Di Marzo V. Bioactive long chainN. Biochim. Biophys. Acta. 1349:1998;101-111.
28. Schmid P. C., Paria B. C., Krebsbach R. J., Schmid H. H. O., Dey S. K. Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation. Proc. Natl. Acad. Sci. USA. 94:1997;4188-4192.
29. Smith P. B., Compton D. R., Welch S. P., Razdan R. K., Mechoulam R., Martin B. R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270:1994;219-227.
30. Fride E., Barg J., Levy R., Saya D., Heldman E., Mechoulam R., Vogel Z. Low doses of anandamides inhibit pharmacological effects of delta-9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther. 272:1995;699-707.
31. 18. Mol. Pharmacol. 44:1993;498-503.
32. Bayewitch M., Avidor-Reiss T., Levy R., Barg J., Mechoulam R., Vogel Z. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. FEBS Lett. 375:1995;143-147.
33. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S. D., Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. USA. 92:1995;3376-3380.
34. Hanus L., Gopher A., Almog S., Mechoulam R. Two new unsatured fatty acid ethanolamides in brain that bind to cannabinoid receptors. J. Med. Chem. 36:1993;3032-3034.
35. Pertwee R., Griffin G., Hanus L., Mechoulam R. Effects of two endogenous fatty acid ethanolamides on mouse vasa deferentia. Eur. J. Pharmacol. 259:1994;115-120.
36. Barg J., Fride E., Hanus L., Levy R., Matus-Leibovitch N., Heldman E., Bayewitch M., Mechoulam R., Vogel Z. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. Eur. J. Pharmacol. 287:1995;145-152.
37. Skaper S. D., Buriani A., Dal Toso R., Petrelli L., Romanello S., Facci L., Leon A. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of exocitotic death in cerebellar granule neurons. Proc. Natl. Acad. Sci. USA. 93:1995;3984-3989.
38. Sheskim T., Hanus L., Slager J., Vogel Z., Mechoulam R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J. Med. Chem. 40:1997;659-667.
39. Showalter V. M., Compton D. R., Martin B. R., Abood M. E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278:1996;989-999.
40. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.-C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 372:1994;686-691.
41. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N. E., Schatz A. R., Gopher A., Almog S., Martin B. R., Compton D. R., Pertwee R. G., Griffin G., Bayewitch M., Barg J., Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:1995;83-90.
42. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonoyl-glycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215:1995;89-97.
43. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 388:1997;773-778.
44. Bisogno T., Sepe N., Melck D., Maurelli S., De Petrocellis L., Di Marzo V. Biosynthesis, release and degradation of the novel endogenous cannabinomimetic metabolite 2-arachidonoyl-glycerol in mouse neuroblastoma cells. Biochem. J. 322:1997;671-677.
45. 2+. Biochem. Biophys. Res. Commun. 229:1996;58-64.
46. Sugiura T., Kodaka T., Kondo S., Tonegawa T., Nakane S., Kishimoto S., Yamashita A., Waku K. Inhibition by 2-arachidonoyl-glycerol, a novel type of possible neuromodulator, of the depolarization-induced increase in intracellular free calcium in neuroblastoma X glioma hybrid NG108-15 cells. Biochem. Biophys. Res. Commun. 233:1997;207-210.
47. 2+. J. Biochem. 122:1997;890-895.
48. Lee M., Yang K. H., Kaminski N. E. Effects of putative cannabinoid receptor ligands, anandamide and 2-arachidonoyl-glycerol on immune function in B6C3F1 mouse splenocytes. J. Pharmacol. Exp. Ther. 275:1995;529-536.
49. Priller J., Briley E. M., Mansouri J., Devane W. A., Mackie K., Felder C. C. Mead ethanolamide, a novel eicosanoid, is a agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors. Mol. Pharmacol. 48:1995;288-292.
50. Pinto J. C., Potie F., Rice K. C., Boring D., Johnson M. R., Evans D. M., Wilken G. H., Cantrell C. H., Howlett A. C. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Mol. Pharmacol. 46:1994;516-522.
51. Edgemond W. S., Campbell W. B., Hillard C. J. The binding of novel phenolic derivatives of anandamide to brain cannabinoid receptors. Prostagl. Leuk. Ess. Fatty Acids. 52:1995;83-86.
52. Adams I. B., Ryan W., Singer M., Thomas B. F., Compton D. R., Razdan R. K., Martin B. R. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J. Pharmacol. Exp. Ther. 273:1995;1172-1181.
53. Abadji V., Lin S., Taha G., Griffin G., Stevenson L. A., Pertwee R. G., Makriyannis A. (R. J. Med. Chem. 37:1994;1889-1893.
54. Thomas B. F., Adams I. B., Mascarella S. W., Martin B. R., Razdan R. K. Structure-activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore. J. Med. Chem. 39:1996;471-479.
55. Berglund B., Fleming P., Rice K., Boring D., Howlett A. C. Investigation of structural analogues of anandamide for binding and activation of cannabinoid receptors. Proc. Int. Cann. Res. Soc. 1997;6.
56. Barnett-Norris J., Guarnieri F., Reggio P. H. Conformational memories and the exploration of biologically relevant conformations of anandamide. Proc. Int. Cann. Res. Soc. 1997;5.
57. Khanolkar A. D., Abadji V., Lin S., Hill W. A., Taha G., Abouzid K., Meng Z., Fan P., Makriyannis A. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J. Med. Chem. 39:1996;4515-4519.
58. Felder C. C., Joyce K. E., Briley E. M., Mansouri J., Mackie K., Blond O., Lai Y., Ma A. L., Mitchell R. L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 48:1995;443-450.
59. Shire D., Calandra B., Rinaldi-Carmona M., Oustric D., Pessegue B., Bonnin-Cabanne O., Le Fur G., Caput D., Ferrara P. Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim. Biophys. Acta. 1307:1996;132-136.
60. Schmid H. H. O., Schmid P. C., Natarajan V. N-acylated glycerophospholipids and their derivatives. Prog. Lipid Res. 29:1990;1-43.
61. Deutsch D. G., Chin S. A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46:1993;791-796.
62. Kruszka K. K., Gross R. W. The ATP- and CoA-independent synthesis of arachidonoylethanolamide. J. Biol. Chem. 269:1994;14345-14348.
63. Devane W. A., Axelrod J. Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proc. Natl. Acad. Sci. USA. 91:1994;6698-6701.
64. Cadas H., Gaillet S., Beltramo M., Venance L., Piomelli D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J. Neurosci. 16:1996;3934-3942.
65. Cadas H., di Tomaso E., Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursor,N. J. Neurosci. 17:1997;1226-1242.
66. Di Marzo V., De Petrocellis L., Sugiura T., Waku K. Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2-arachidonoyl-glycerol, in mouse neuroblastoma cells. Biochem. Biophys. Res. Commun. 227:1996;281-288.
67. Schmid P. C., Reddy P. V., Natarajan V., Schmid H. H. O. Metabolism ofN. J. Biol. Chem. 258:1983;9302-9306.
68. Kuwae T., Schmid P. C., Schmid H. H. O. Alterations of fatty acyl turnover in macrophage glycerolipids induced by stimulation: Evidence for enhanced recycling of arachidonic acid. Biochim. Biophys. Acta. 1344:1997;74-86.
69. Schmid P. C., Zuzarte-Augustin M. L., Schmid H. H. O. Properties of rat liverN. J. Biol. Chem. 260:1985;14145-14149.
70. Kurahashi Y., Ueda N., Suzuki H., Suzuki M., Yamamoto S. Reversible hydrolysis and synthesis of anandamide demonstrated by recombinant rat fatty acid amide hydrolase. Biochem. Biophys. Res. Commun. 237:1997;512-515.
71. Arreaza G., Devane W. A., Omeir R. L., Sajnani G., Kunz J., Cravatt B. F., Deutsch D. G. The cloned rat hydrolytic enzyme responsible for the breakdown of anandamide also catalyzes its formation via the condensation of arachidonic acid and ethanolamine. Neurosci. Lett. 234:1997;59-62.
72. Snyder F. Metabolism, regulation and function of ether-linked glycerolipids and their bioactive species. Biochemistry of Lipids, Lipoproteins and Membranes. 1991;Elsevier, Amsterdam. p. 241-267.
73. Schmid P. C., Schwindenbammer D., Krebsbach R. J., Schmid H. H. O. Alternative pathways of anandamide biosynthesis in rat testes. Chem. Phys. Lipids. 92:1998;27-35.
74. Paria B. C., Deutsch D. G., Dey S. K. The uterus is a potential site for ananadamide synthesis and hydrolysis: differential profiles of ananadamide synthase and hydrolase activities in the mouse uterus during the periimplantation period. Mol. Reprod. Develop. 45:1996;183-192.
75. Farooqui A. A., Taylor W. A., Horrocks L. A. Characterization and solubilization of membrane-bound diacylglycerol lipases from bovine brain. Int. J. Biochem. 18:1986;991-997.
76. Meldolesi J., Westhead E. W. The nervous system, nerve cells and their models. Mitchell R. H., Drummond A. H., Downes C. P. Inositol Lipids in Cell Signalling. 1989;311-336 Academic Press, New York.
77. 1. J. Neurochem. 61:1993;1874-1881.
78. Desarnaud F., Cadas H., Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes: Identification and partial characterization. J. Biol. Chem. 270:1995;6030-6035.
79. Ueda N., Kurahashi Y., Yamamoto S., Tokunaga T. Partial purification and characterization of the porcine brain enzyme hydrolazing and synthesizing anandamide. J. Biol. Chem. 270:1995;23823-23827.
80. Hillard C. J., Wilkison D. M., Edgemond W. S., Campbell W. B. Characterization of the kinetics and distribution ofN. Biochim. Biophys. Acta. 1257:1995;249-256.
81. Watanabe K., Kayano Y., Matsunaga T., Yamamoto I., Yoshimura H. Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids. Biol. Pharmaceut. Bull. 19:1997;1109-1111.
82. Maurelli S., Bisogno T., De Petrocellis L., Di Luccia A., Marino G., Di Marzo V. Two novel class of neuroactive fatty acid amides are substates for mouse neuroblastoma anandamide amidohydrolase. FEBS Lett. 377:1995;82-86.
83. Cravatt B. F., Prospero-Garcia O., Siuzdak G., Gilula N. B., Henriksen S. J., Boger D. L., Lerner R. A. Chemical characterization of a family of brain-lipids that induce sleep. Science. 268:1995;1506-1509.
84. Matsuda S., Kanemitsu N., Nakamura A., Mimura Y., Ueda N., Kurahashi Y., Yamamoto S. Metabolism of anandamide, an endogenous cannbinoid receptor ligand, in porcine ocular tissues. Exp. Eye Res. 64:1997;707-711.
85. Katayama K., Ueda N., Kurahashi Y., Suzuki H., Yamamoto S., Kato I. Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine. Biochim. Biophys. Acta. 1347:1997;212-218.
86. Lang W. S., Qin C., Hill W. A. G., Lin S. Y., Khanolkar A. D., Makriyannis A. High performance liquid chromatography determination of anandamide amidase activity in rat brain microsomes. Anal. Biochem. 238:1996;40-45.
87. Thumser A. E. A., Voysey J., Wilton D. C. A fluorescence displacement assay for the measurement of arachidonoyl ethanolamide (anandamide) and oleoyl amide (octadecenoamide) hydrolysis. Biochem. Pharmacol. 53:1997;433-435.
88. Koutek B., Prestwich G. D., Howlett A. C., Chin S. A., Salehani D., Akhavan N., Deutsch D. G. Inhibitors of arachidonyl ethanolamide hydrolisis. J. Biol. Chem. 269:1994;22937-22940.
89. Cravatt B. F., Giang D. K., Mayfield S. P., Boger D. L., Lerner R. A., Gilula N. B. Molecular characterization of an enzyme that degrades neuromodulatory fatty acid amides. Nature. 384:1996;83-87.
90. Patterson J. E., Ollman I. R., Cravatt B. F., Boger D. L., Wong G.-H., Lerner R. A. Inhibition of oleamide hydrolase catalyzed hydrolysis of the endogenous sleep-inducing lipidcis. J. Am. Chem. Soc. 118:1996;5938-5945.
91. Thomas E. A., Cravatt B. F., Danielson P. E., Gilula N. B., Sutcliffe J. G. Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system. J. Neurosci. Res. 50:1997;1047-1052.
92. Giang D. K., Cravatt B. F. Molecular characterization of human and mouse fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA. 94:1997;2238-2242.
93. Hampson A. J., Hill W. A., Zan-Phillips M., Makriyannis A., Leung E., Eglen R. M., Bornheim L. M. Anandamide hydroxylation by brain lipoxygenase: Metabolite structures and potencies at the cannabinoid receptor. Biochem. Biophys. Acta. 1259:1995;173-179.
94. Bornheim L. M., Kim K. Y., Chen B., Correia M. A. The effect of cannabidiol on mouse hepatic microsomal cytochrome P-450-dependent anandamide metabolism. Biochem. Biophys. Res. Commun. 197:1993;740-746.
95. Ueda N., Yamamoto K., Yamamoto S., Tokunaga T., Shirakawa E., Shinaki H., Ogawa M., Sato T., Kudo I., Inoue K., Takizawa H., Nagano T., Hirobe M., Saito H. Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist. Biochem. Biophys. Acta. 1254:1995;127-134.
96. 2. J. Biol. Chem. 272:1997;21181-21186.
97. Edgemond W. S., Hillard C. J., Falck J. R., Kearn C. S., Campbell W. B. Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonoyl ethanolamide (anandamide): Their affinities for cannabinoid receptors and pathways of activation. Mol. Pharmacol. 54:1998;180-188.
98. Willoughby K. A., Moore S. F., Martin B. R., Ellis E. F. The biodisposition and metabolism of anandamide in mice. J. Pharmacol. Exp. Ther. 282:1997;243-247.
99. Hillard C. J., Edgemond W. S., Jarrahian A., Campbell W. B. Accumulation ofNvia. J. Neurochem. 68:1997;631-638.
100. Beltramo M., Stella N., Calignano A., Lin S. Y., Makriyannis A., Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 277:1997;1094-1097.
101. Di Marzo V., De Petrocellis L., Bisogno T., Melck D., Sepe N. Cannabimimetic fatty acid derivatives: biosynthesis and catabolism. Riemersma R. A., Wilson R. Proceedings of the 4th International Congress on Essential Fatty Acids and Eicosanoids. 1997;Am. Oil Chem. Soc. Press, Champaign.
102. Goparaju S. K., Ueda N., Yamaguchi H., Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett. 422:1998;69-73.
103. Di Marzo V., Bisogno T., Sugiura T., Melck D., De Petrocellis L. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by nervous and peripheral cells: connections with anandamide. Biochem. J. 331:1998;15-19.
104. Shaw E. Peptidyl diazomethanes as inhibitors of cysteine and serine proteinases. Methods Enzymol. 244:1994;649-656.
105. Bromme D., Demuth H.-U. N,O. Methods Enzymol. 244:1994;671-685.
106. De Petrocellis L., Melck D., Ueda N., Maurelli S., Kurahashi Y., Yamamoto S., Marino G., Di Marzo V. Novel inhibitors of brain, neuronal and basophilic anandamide aminohydrolase. Biochem. Biophys. Res. Commun. 231:1997;82-88.
107. Deutsch D. G., Omeir R., Arreaza G., Salehani D., Prestwich G. D., Huang Z., Howlett A. C. Methyl-arachidonyl-fluorophosphonate: A potent irreversible inhibitor of anandamide amidase. Biochem. Pharmacol. 53:1997;255-260.
108. Deutsch D. G., Lin S., Hill W. A. G., Morse K. L., Salehani D., Arreaza G., Omeir R. L., Makriyannis A. Fatty acid sulphonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem. Biophys. Res. Commun. 231:1997;217-221.
109. Beltramo M., di Tomaso E., Piomelli D. Inhibition of anandamide hydrolysis in rat brain tissue by (E)-6-(bromoethylene) tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one. FEBS Lett. 403:1997;263-267.
110. Fowler C. J., Stenstrom A., Tiger G. Ibuprofen inhibits the metabolism of the endogenous cannabimimetic agent anandamide. Pharmacol. Toxicol. 80:1997;103-107.
111. De Petrocellis L., Melck D., Ueda N., Kurahashi Y., Bisogno T., Yamamoto S., Di Marzo V. Brain and peripheral anandamide amidohydrolase and its inhibition by synthetic arachidonate analogues. Adv. Exp. Med. Biol. 433:1997;259-263.
112. Okuyama H., Kobayashi T., Watanabe S. Dietary fatty acids - The n-6/n-3 balance and chronic elderly diseases. Excess linolenic acid and relative n-3 deficiency syndrome seen in Japan. Prog. Lipid Res. 35:1997;409-457.
113. di Tomaso E., Beltramo M., Piomelli D. Brain cannabinoids in chocolate. Nature. 382:1997;677-678.
114. Bisogno T., Sepe N., De Petrocellis L., Mechoulam R., Di Marzo V. The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. Biochem. Biophys. Res. Commun. 239:1997;473-479.
115. Mechoulam R., Fride E., Hanus L., Sheskin T., Bisogno T., Di Marzo V., Bayewitch M., Vogel Z. Anandamide may mediate sleep induction. Nature. 389:1997;25-26.
116. Ben-Shabat S., Fride E., Sheskin T., Tamiri T., Rhee M.-H., Vogel Z., Bisogno T., De Petrocellis L., Di Marzo V., Mechoulam R. An entourage effect: Inactive endogenous fatty acid glycerol esters benhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 253:1998;23-31.
117. Fride E., Bisogno T., Di Marzo V., Bayewitch M., Vogel Z., Mechoulam R. Anandamide: Mediator of the effects of oleamide (a sleep factor) and of chocolate. Soc. Neurosci. Abstr. 23:1997;1230.
118. Koga D., Santa T., Hagiwara K., Imai K., Takizawa H., Nagano T., Hirobe M., Ogawa M., Sato T., Inoue K., Kudo I. High performance liquid chromatography and fluorimetric detection of arachidonylethanolamide (anandamide) and its analogues, derivatized with 4-(N-chloroformylmethyl-N-methyl)amino-7-N-,N-dimethylaminosulphonyl-2,1,3-ben zoxadiazole (DBD-COCI). Biomed. Chromatogr. 9:1995;56-57.
119. Fontana A., Di Marzo V., Cadas H., Piomelli D. Analysis of ananadamide, an endogenous cannabinoid substance, and other naturalN. Prostagl. Leuk. Ess. Fatty Acids. 53:1995;301-308.
120. Kempe K., Hsu F. F., Bohrer A., Turk J. Isotope dilution mass spectrometric measurements indicate that arachidonyletanolamide, the proposed endogenous ligand of the cannabinoid receptor, accumulates in rat brain tissue post mortem but is contained at low levels in or absent from fresh tissue. J. Biol. Chem. 271:1996;17287-17295.
121. Koga D., Santa T., Fukushima T., Homma H., Imai K. Liquid chromatographic-atmospheric pressure chemical ionization mass spectrometric determination of anandamide and its analogs in rat brain and peripheral tissues. J. Chromatogr. B. Biomed. Appl. 690:1997;7-13.
122. Wagner J. A., Varga K., Ellis E. F., Rzigalinski B. A., Martin B. R., Kunos G. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature. 390:1997;518-521.
123. Bisogno T., Melck D., De Petrocellis L., Bognow M. Yu., Gretskaya N. M., Bezvglov V. V., Sitachitta N., Gerwick W. H., Di Marzo V. Arachidonoyl serotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem. Biophys. Res. Commun. 248:1998;515-522.